INDUSTRIES
Open source license risk for private equity portfolios.
Open source license risk for private equity is rarely on the model, yet it can move a valuation and shape a hold. Across a portfolio, relicensed and copyleft components create exposure that surfaces at the worst time, in diligence on exit or in an audit. We work from the buyer side to find it early, price it, and contain it.
A private equity firm carries open source license risk twice over. It carries it at entry, in the target it is about to buy, and it carries it through the hold, across every portfolio company already owned. The risk is the same in kind: software that has relicensed from an open license to source available terms, or copyleft components that conflict with how a company ships, can require unbudgeted spend to stay compliant. What makes the private equity case distinct is scale and timing. One relicensing event can touch many companies at once, and the cost lands during a period when value creation, not surprise remediation, is the plan.
Why open source risk reaches the deal model
A valuation assumes a company can carry on as it is. Open source exposure breaks that assumption when a dependency carries terms the current operating model does not satisfy. The Business Source License restricts competitive production use, and the Server Side Public License carries a strong service condition. As of August 2023 HashiCorp moved Terraform, Vault, Consul, Nomad and Packer to the Business Source License 1.1. As of March 2024 Redis moved to a model that includes the Server Side Public License, with the fork Valkey. Elasticsearch and Kibana moved to the Server Side Public License and the Elastic License in 2021, with the fork OpenSearch, and MongoDB moved to the Server Side Public License in 2018. A portfolio company running any of these on an old assumption holds exposure the financials do not show. The path from that exposure to the price is set out in open source risk and deal valuation.
Diligence at entry
The cheapest time to find open source exposure is before the price is fixed. During diligence, a dependency map and license review, with a remediation cost attached, gives the deal team room to negotiate a price adjustment, an escrow, or a condition to close while the seller still wants the deal done. After close, the same finding is the buyer's problem alone, paid out of the returns the deal was meant to deliver. A buyer side open source M and A due diligence engagement produces that number in time to matter, and the foundational map comes from an open source license risk assessment.
A common method across the portfolio
Where private equity gains the most is standardization. Assessing each portfolio company on a common method makes exposure comparable across the book. When a project relicenses, the firm can ask one question and answer it for every company at once: who runs this, in what version, and what does the change cost us. That is the difference between scrambling company by company and managing a known position. A portfolio that standardized this approach is described in the case study on how a private equity portfolio standardized open source diligence.
Containment during the hold
When exposure is found, the response is rarely a single answer. For each relicensed component the options are a commercial license negotiated from the buyer side, a migration to a community fork such as OpenTofu, Valkey, or OpenSearch, or removing the dependency. Each is weighed on cost, license posture, and timeline, so the path chosen holds at exit diligence rather than reappearing as a red flag. Our open source remediation advisory sequences that work across companies so it fits the value creation plan instead of fighting it.
Independent and on the buyer side
We are an independent open source license risk advisory. We take no vendor fees and resell nothing. We are paid only by the buyer, which means the assessment of whether to license, migrate, or remove is made on the portfolio's interest alone. This is commercial and licensing risk advisory, not legal advice. For interpretation of license terms and compliance positions, we recommend the firm's own counsel.
COMMON QUESTIONS
Questions buyers ask.
What is open source license risk for private equity?
Open source license risk for private equity is the exposure that relicensed and copyleft components create across a portfolio. A target or portfolio company may depend on software that has moved to source available terms, which can require a commercial license, a migration, or a source disclosure, each carrying a cost that affects valuation and the hold.
When should a private equity firm assess open source risk?
Assess during diligence, before the price is fixed, so a remediation cost can be negotiated or covered. Then reassess across the hold, because projects relicense over time and a clean target can develop exposure while it is owned.
How does open source risk affect a portfolio company valuation?
It affects valuation when a dependency requires unbudgeted spend to stay compliant, such as a commercial license under the Business Source License or the Server Side Public License, or a migration away from a relicensed component. Priced in diligence, the exposure becomes a negotiable line rather than a post close surprise.
Can open source diligence run across a whole portfolio?
Yes. A standardized approach maps dependencies and license states across portfolio companies on a common method, so exposure is comparable across the book and a relicensing event can be assessed against every company at once.
CONTAINMENT
Map open source exposure across the portfolio.
A confidential open source license risk assessment. Independent, buyer side, paid only by you.
Not ready to talk? Read the free open source license risk guides first.